U.S. FDA Grants Brukinsa (zanubrutinib) Approval in Waldenström’s Macroglobulinemia
CAMBRIDGE, Mass. & BEIJING, September 01, 2021–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing …
Home »
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
NEW YORK–(BUSINESS WIRE) October 27, 2020 — Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration …